Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2017

Open Access 01-12-2017 | Case report

Reversible diabetes mellitus induced by use of, and improved after discontinuation of, the antiretroviral medication zidovudine: a case report

Authors: Kentaro Iwata, Wataru Ogawa

Published in: Journal of Medical Case Reports | Issue 1/2017

Login to get access

Abstract

Background

With the advent of effective antiretroviral therapy, the care of patients with human immunodeficiency virus infection became more like that of other chronic diseases. Diabetes mellitus can also occur as one of the chronic illnesses affecting patients with human immunodeficiency virus infection. We report a case of newly developed diabetes mellitus in a patient with human immunodeficiency virus infection, most likely caused by the nucleoside analogue zidovudine, and its improvement after discontinuation of zidovudine.

Case presentation

A Chinese man in his 30s visited our outpatient clinic for routine follow-up of human immunodeficiency virus infection. Blood tests showed hyperglycemia with a glucose level of 31.8 mmol/L and hemoglobin A1c of 8.5%. He was diagnosed with diabetes mellitus and treated with oral diabetic medications. The use of zidovudine was suspected as the cause of his diabetes, and it was replaced by other antiretroviral medication. His hyperglycemia improved, and he now no longer requires diabetic medications.

Conclusions

Diabetes mellitus can develop with the use of antiretroviral medications, but its occurrence associated with use of zidovudine is quite rare. Healthcare personnel should be aware of this rare, yet important, side effect.
Literature
2.
go back to reference Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31:1185–93.CrossRefPubMed Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31:1185–93.CrossRefPubMed
4.
go back to reference Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713–4.CrossRefPubMed Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713–4.CrossRefPubMed
5.
go back to reference Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.CrossRefPubMed Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.CrossRefPubMed
6.
go back to reference Lee ECC, Walmsley S, Fantus IG. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient case report and review. CMAJ. 1999;161:161–4.PubMedPubMedCentral Lee ECC, Walmsley S, Fantus IG. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient case report and review. CMAJ. 1999;161:161–4.PubMedPubMedCentral
7.
go back to reference Palma-Aguirre A, Halabe-Cherem J, Nellen-Hummel H, Aburto-Mejı́a E, Ibarra-Herrera E, Ponce-Monter H. Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection. Arch Med Res. 2000;31:81–4.CrossRefPubMed Palma-Aguirre A, Halabe-Cherem J, Nellen-Hummel H, Aburto-Mejı́a E, Ibarra-Herrera E, Ponce-Monter H. Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection. Arch Med Res. 2000;31:81–4.CrossRefPubMed
8.
go back to reference Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111–9.CrossRefPubMed Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111–9.CrossRefPubMed
9.
go back to reference Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360–5.CrossRefPubMed Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360–5.CrossRefPubMed
11.
go back to reference Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.CrossRefPubMed Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.CrossRefPubMed
12.
go back to reference De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.CrossRefPubMedPubMedCentral De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.CrossRefPubMedPubMedCentral
13.
go back to reference Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, Liu WC, et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med. 2009;10:302–9.CrossRefPubMed Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, Liu WC, et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med. 2009;10:302–9.CrossRefPubMed
14.
go back to reference Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, et al. New-onset diabetes and antiretroviral treatments in HIV-infected adults in Thailand. J Acquir Immune Defic Syndr. 2015;69:453–9.CrossRefPubMed Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, et al. New-onset diabetes and antiretroviral treatments in HIV-infected adults in Thailand. J Acquir Immune Defic Syndr. 2015;69:453–9.CrossRefPubMed
15.
go back to reference Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227–36.CrossRefPubMed Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227–36.CrossRefPubMed
16.
go back to reference Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207–15.CrossRefPubMed Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207–15.CrossRefPubMed
17.
go back to reference Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250–7.CrossRefPubMed Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250–7.CrossRefPubMed
18.
go back to reference Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015;60:453–62.CrossRefPubMed Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015;60:453–62.CrossRefPubMed
19.
go back to reference Block LH. Polymedicine: known and unknown drug interactions. J Am Geriatr Soc. 1982;30(11 Suppl):S94–8.CrossRefPubMed Block LH. Polymedicine: known and unknown drug interactions. J Am Geriatr Soc. 1982;30(11 Suppl):S94–8.CrossRefPubMed
Metadata
Title
Reversible diabetes mellitus induced by use of, and improved after discontinuation of, the antiretroviral medication zidovudine: a case report
Authors
Kentaro Iwata
Wataru Ogawa
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2017
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-017-1326-z

Other articles of this Issue 1/2017

Journal of Medical Case Reports 1/2017 Go to the issue